Literature DB >> 20882371

OnabotulinumtoxinA: preventive treatment for chronic migraine.

Shih-Pin Chen1, Jong-Ling Fuh, Shuu-Jiun Wang.   

Abstract

Entities:  

Year:  2011        PMID： 20882371     DOI： 10.1007/s11916-010-0150-6

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN： 1534-3081


× No keyword cloud information.
  17 in total

Review 1.  Physiology and pharmacology of therapeutic botulinum neurotoxins.

Authors:  K Roger Aoki
Journal:  Curr Probl Dermatol       Date:  2002

2.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

3.  Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis.

Authors:  Parisa Gazerani; Sammy Au; Xudong Dong; Ujendra Kumar; Lars Arendt-Nielsen; Brian E Cairns
Journal:  Pain       Date:  2010-08-21       Impact factor: 6.961

4.  Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine.

Authors:  Elza Magalhães; Carla Menezes; Mauricio Cardeal; Ailton Melo
Journal:  Clin Neurol Neurosurg       Date:  2010-04-18       Impact factor: 1.876

5.  Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.

Authors:  W J Binder; M F Brin; A Blitzer; L D Schoenrock; J M Pogoda
Journal:  Otolaryngol Head Neck Surg       Date:  2000-12       Impact factor: 3.497

6.  Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen D Silberstein; Richard B Lipton; David W Dodick; Frederick G Freitag; Nabih Ramadan; Ninan Mathew; Jan L Brandes; Marcelo Bigal; Joel Saper; Steven Ascher; Donna M Jordan; Steven J Greenberg; Joseph Hulihan
Journal:  Headache       Date:  2007-02       Impact factor: 5.887

Review 7.  Evidence based medicine on the use of botulinum toxin for headache disorders.

Authors:  W J Schulte-Mattler; E Leinisch
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

Review 8.  Evidence for antinociceptive activity of botulinum toxin type A in pain management.

Authors:  K Roger Aoki
Journal:  Headache       Date:  2003 Jul-Aug       Impact factor: 5.887

9.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292

10.  A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.

Authors:  Ninan T Mathew; Sayyed Farhan A Jaffri
Journal:  Headache       Date:  2009 Nov-Dec       Impact factor: 5.887
View more
  2 in total

1.  Dispute settlement understanding on the use of Botox in chronic migraine.

Authors:  Paolo Martelletti
Journal:  J Headache Pain       Date:  2011-02       Impact factor: 7.277

Review 2.  Botulinum toxins for the prevention of migraine in adults.

Authors:  Clare P Herd; Claire L Tomlinson; Caroline Rick; W J Scotton; Julie Edwards; Natalie Ives; Carl E Clarke; Alexandra Sinclair
Journal:  Cochrane Database Syst Rev       Date:  2018-06-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.